register

Digital & Innovation

MedTech startup announces TGA approval of AI-powered imaging analysis technology

Health Industry Hub | February 8, 2021 |
[Total: 1    Average: 5/5]

Digital & Innovation: See-Mode Technologies, a MedTech startup based in Australia and Singapore empowering clinicians to better predict stroke, has received regulatory approvals from the Therapeutic Goods Administration (TGA) and CE Mark, for the Augmented Vascular Analysis (AVA) software.

AVA uses Artificial Intelligence (AI) to perform automated analysis and reporting of vascular ultrasound, CT or MRI scans, enabling clinicians to interpret and report on these scans more efficiently and with higher quality.

Despite the importance of ultrasound studies for diagnosis and treatment of patients with vascular conditions, analysis and reporting of these scans are primarily done manually, using pen and paper.

Through its use of deep learning, text recognition, and signal processing, AVA improves the speed and quality of the process significantly. With a single click and in less than a minute, AVA can analyse a full vascular ultrasound scan, minimising the need for manual drawings. This helps to augment the clinical workflow, resulting in greater overall productivity, accuracy, and improved patient outcome.

“Since See-Mode’s inception, we have seen that clinicians are increasingly looking for ways to speed up their workflow while improving patient care. Thus, we are proud that AVA has obtained CE Mark and TGA approval – on top of the earlier clearances from FDA and HSA – to help with analysis and reporting of vascular studies,” said Dr Sadaf Monajemi, Co-Founder and Director, See-Mode Technologies.

“Achieving four regulatory approvals as a three-year-old startup was no easy feat. This clearly demonstrates the scientific rigour with which we have built and validated our product and we are extremely thankful to have the support of our clinical partners. Having reached this significant milestone for See-Mode, we look forward to continuing our commercial growth trajectory in Europe and Australia.”

See-Mode has embarked on research partnerships with healthcare institutions such as Austin Health and Royal Melbourne Hospital in Australia and the National University Hospital and Changi General Hospital in Singapore, for further validation of its algorithms and models to assist clinicians in image interpretation and stroke prediction.

See-Mode is continuously adding more image interpretation and reporting capabilities to AVA and expanding the product’s capabilities to new clinical use cases. Continuing on its mission to assist doctors in predicting and preventing stroke, See-Mode is currently running clinical validation studies for its future algorithms on the detection of high risk plaques and high risk blood flow with partners across Australia, Singapore, Europe and the United States.

See-Mode aims to rapidly scale its business across its core markets, namely Australia, Europe, the United States and Singapore.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Digital & Innovation

Healthcare Technology Digital Innovations - Shifts in Pharma’s digital health landscape - Deep dive with Dr Ramin Rafiei

Shifts in Pharma’s digital health landscape – Deep dive with Dr Ramin Rafiei

Health Industry Hub | March 1, 2021 |

In this Health Industry Hub interview, Dr Ramin Rafiei takes us on a deep dive into the current digital health […]

More


News & Trends - Pharmaceuticals

Pharma News - Boehringer Ingelheim reduces carbon footprint with launch of reusable inhaler

Boehringer Ingelheim reduces carbon footprint with launch of reusable inhaler

Health Industry Hub | March 1, 2021 |

Pharma News: Boehringer Ingelheim has reinforced its commitment to increased sustainability within the healthcare sector, launching a more eco-friendly version […]

More


Medical

$1.3 billion manufacturing funding opens for medicines and medical devices

Health Industry Hub | March 1, 2021 |

Medical News: The Morrison Government is backing Australia’s medical products manufacturers to grow and create new jobs, with applications for […]

More


News & Trends - Medical Technology

MedTech News - $100 million funding for major advances in medical technology

$100 million funding for major advances in medical technology

Health Industry Hub | March 1, 2021 |

MedTech News: $100 million is being invested into the development of new medical technologies to improve diagnosis and treatment of […]

More